We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High NT-proBNP Paradoxically Shows Lower Risk in Early Pregnancy

By LabMedica International staff writers
Posted on 03 Feb 2022
Print article
Image: Elecsys Pro-BNP II Gen Assay may identify higher natriuretic peptide levels during early pregnancy were better for maternal blood pressure (Photo courtesy of Biolab Diagnostics)
Image: Elecsys Pro-BNP II Gen Assay may identify higher natriuretic peptide levels during early pregnancy were better for maternal blood pressure (Photo courtesy of Biolab Diagnostics)
Hypertensive disorders of pregnancy are associated with future cardiovascular disease, perhaps because of subclinical cardiac dysfunction before pregnancy leading to impaired adaptation to pregnancy.

N-terminal pro-brain natriuretic peptide (NT‐proBNP) is emerging as a diagnostic tool in the diagnosis of heart failure. It increases with ventricular volume expansion and pressure overload. It is raised in several cardiac conditions, but most studies have focused predominantly on systolic dysfunction in comparatively young patients.

Clinical Scientists at the University of Pittsburgh School of Medicine (Pittsburgh, PA, USA) and their colleagues investigated whether higher concentrations NT-proBNP in early pregnancy would be associated with hypertensive disorders of pregnancy and hypertension 2 to 7 years post-partum. A total of 4,103 nulliparous women with complete data and no pre-pregnancy hypertension or diabetes, who were treated at eight clinical sites, were included in a study. Women were followed up with for 2 to 7 years after pregnancy. Data were collected from October 2010 to October 2017, and data were analyzed from August 2020 to November 2021. NT-proBNP concentrations were measured using an electrochemiluminescence immunoassay from a first-trimester blood sample.

The scientists reported the mean ± SD age of the study participants was 27.0 ±5.6 years. Among these women, 909 (22.2%) had an adverse pregnancy outcome, and 817 (19.9%) had hypertension at the follow-up visit. Higher NT-proBNP concentrations were associated with a lower risk of hypertensive disorders of pregnancy (adjusted odds ratio per doubling, 0.81; 95% CI, 0.73-0.91), which persisted after adjustment for age, self-reported race and ethnicity, early-pregnancy body mass index, smoking, and aspirin use. Similarly, higher NT-proBNP concentration in early pregnancy was also associated with a lower risk of incident hypertension 2 to 7 years after delivery; adjusted odds ratio per doubling, 0.84, an association that persisted after controlling for confounders, including hypertensive disorders of pregnancy.

Alisse K. Hauspurg, MD, an obstetrician-gynecologist and lead author of the study, said, “Women who experienced adverse pregnancy outcomes had lower first-trimester concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), median 56.0 pg/mL, a biomarker for subclinical cardiac dysfunction, versus 63.0 pg/mL for women who did not have these outcomes.”

The authors concluded that in this cohort study, higher NT-proBNP concentrations in early pregnancy were associated with a lower risk of hypertensive disorders of pregnancy and hypertension 2 to 7 years post-partum. These findings suggest that normal early-pregnancy cardiovascular physiology, as assessed by NT-proBNP concentration, may provide biologic insights into both pregnancy outcome and cardiovascular disease risk. The study was published on January 19, 2022 in the journal JAMA Cardiology.

Related Links:
University of Pittsburgh School of Medicine

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.